NOXXON RAISES AMOUNT OF EUR 521 K IN ITS RIGHTS ISSUE ADJUSTMENT IN CLINICAL DEVELOPMENT TIMELINES AND BUSINESS PROSPECTS Berlin, Germany, July 19, 2019, 8.30 p.m. CEST - NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces today the results of its rights issue for a limited amount of 521 K. Following the subscription period, which ended on July 17, 2019, the capital increase raised a limited amount of EUR 521 K, i.e. 801,494 shares at a price of EUR 0.65 per share, including: 358,011 new shares subscribed to on an irreducible basis, 81,560 new shares subscribed to on a reducible...
|
